CN1081888A - Treatment commonly encountered diseases of internal department, the apoplexy of frequently-occurring disease and the Chinese patent medicine tablet of sequela - Google Patents
Treatment commonly encountered diseases of internal department, the apoplexy of frequently-occurring disease and the Chinese patent medicine tablet of sequela Download PDFInfo
- Publication number
- CN1081888A CN1081888A CN 93100576 CN93100576A CN1081888A CN 1081888 A CN1081888 A CN 1081888A CN 93100576 CN93100576 CN 93100576 CN 93100576 A CN93100576 A CN 93100576A CN 1081888 A CN1081888 A CN 1081888A
- Authority
- CN
- China
- Prior art keywords
- radix
- caulis
- apoplexy
- sequela
- frequently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to the Chinese patent medicine tablet of treatment usefulness of the apoplexy sequela of commonly encountered diseases of internal department, frequently-occurring disease.It is characterized in that prescription is Radix Salviae Miltiorrhizae 7-15%, Rhizoma Chuanxiong 2-4%, Radix Angelicae Sinensis 2-4%, Flos Carthami 0.7-1.5%, Caulis Spatholobi 7-15%, Caulis Trachelospermi 4-8%, Radix Clematidis 2.5-4.5%, Herba Lycopodii 4.5-8.5%, Caulis Lonicerae 7-15%, Radix Cyathulae 7-15%, Fructus Chaenomelis 8-7%, Pheretima 6.5-13.6%, Bombyx Batryticatus 2.3-4.3%, Eupolyphaga Seu Steleophaga 2.3-4.3%, Scorpio 0.6-1.6%, Scolopendra 0.3-0.7%, Semen Persicae 2.3-4.5%, Fructus Leonuri 2.5-4.0%, Bungarus Parvus 0.10-0.30%.The present invention prescription is made a distinction between the important and the lesser one, and compatibility is reasonable, and curative effect is obvious, acts on gentlely, and side effect is little, is convenient to take and carry.
Description
The present invention relates to the Chinese patent medicine tablet of the apoplexy sequela treatment usefulness of commonly encountered diseases of internal department, frequently-occurring disease.
At present, apoplexy for commonly encountered diseases of internal department, frequently-occurring disease, making significant headway aspect the suffering from acute stroke rescue, especially it is fine to rub combined therapy of Chinese and Western medicine curative effect, but for apoplexy and in remain in some problems in the treatment of sequela such as wind-induced hemiplegia, curative effect is not satisfactory, and the patient takes Chinese medicine decoction for a long time simultaneously, brings many inconvenience to patient and relatives.
The purpose of this invention is to provide a kind of to apoplexy and in sequela convalescent care instant effect such as wind-induced hemiplegia, curative effect is obvious, side effect is little, the medicine of taking convenience.
The medicine of technical solution of the present invention and prescription thereof are to utilize on the basis of the raw material of sugar-coat outside the preparation of the prior art, and each composition and the percentage by weight thereof of its prescription are:
Radix Salviae Miltiorrhizae 7-15%, Rhizoma Chuanxiong 2-4%, Radix Angelicae Sinensis 2-4%, Flos Carthami 0.7-1.5%, Caulis Spatholobi 7-15%, Caulis Trachelospermi 4-8%, Radix Clematidis 2.5-4.5%, Herba Lycopodii 4.5-8.5%, Caulis Lonicerae 7-15%, Radix Cyathulae 7-15%, Fructus Chaenomelis 3-7%, Pheretima 6.5-13.6%, Bombyx Batryticatus 2.3-4.3%, Eupolyphaga Seu Steleophaga 2.8-4.3%, Scorpio 0.6-1.5%, Scolopendra 0.3-0.7%, Semen Persicae 2.3-4.5%, Fructus Leonuri 2.5-4.0%, gold thread Agkistrodon 0.1-0.3%.
The cause of disease that forms apoplexy is that mechanism of qi is disorderly contrary, hyperactivity of YANG due to deficiency of YIN, qi depression to blood stasis, the turbid resistance network of expectorant.Blood stasis and expectorant are turbid to be the pathological metabolism product, is again the cause of disease simultaneously, and wherein gas, blood, paralysis reciprocal causation is the feature of primary disease.Apoplexy divides hemorrhagic and ischemic two big classes, and all there are two pathology cores in its acute stage, convalescent period and sequela stage.The change of first blood operation, any way of blood fortune changes all can produce blood stasis.Rise absurd row, hemorrhage blood stasis etc. as stasis blood stasis, blood stasis due to qi deficiency, QI rising in reverse order blood.Blood stasis is tangible, and detention can cause obstructed in body.Its two expectorant is turbid, and incoming road has two: one for blood flow water poly-, blood stasis water, poly-then give birth to expectorant, turbid dirt is life thereupon.If expectorant disease and blood, expectorant stops blood stasis, and blood stasis then gas is more stagnant.The present invention promptly catches this pathology core of blood stasis, takes based on blood circulation promoting and blood stasis dispelling, and it is auxilliary that dredge the meridian passage reduces phlegm, and relieves dizziness, high fever, infantile convulsions, epilepsy, etc. to decide the principles of formulating prescriptions that convulsion makes for assistant.
From prescription, medicine roughly is divided three classes according to the rule of treatment: (one) drug for invigorating blood circulation and eliminating stasis, be stroke patient because of blood stagnancy due to deficiency of QI, stasis of blood resistance passages through which vital energy circulates and hemiplegia occurs.Therefore remove the necessary blood circulation and channel invigorating of disease, dispel the stasis of blood and stagnate.Semen Persicae, Flos Carthami have very strong clots absorbing function, go into Liver Channel and walk blood system and can declare promoting blood circulation.Radix Angelicae Sinensis, Rhizoma Chuanxiong are medicine first choice of the blood circulation promoting and blood stasis dispelling, its gas fragrance, and property is walked to scurry, but dissipating blood stasis blood; Radix Salviae Miltiorrhizae is bitter and be slightly cold, can the removing heat from blood blood stasis removing; The Radix Cyathulae dissipating blood stasis to promote menstruationg, strong muscles and bones, easing joint movement, the descending lower limb that reach of priming, more than a few flavor medicines core that is prescription.(2) dredge the meridian passage medicine, stroke patient be because of closing in the winddamp phlegm heresy, multiple abscess muscle arteries and veins, and stagnant and obstructed, the gas that battalion defends can not moisten foster podomere, causes paralysis or apathetic, and articular instability so need dredge the meridian passage, dispels the wind and falls wet function with the recovery limbs.Agkistrodon can be dispeled the wind, and the arresting convulsion of stimulating the menstrual flow is only taken out, sweet-salty temperature.Sweet temperature is supporing yang with ventilation, and salty temperature is gone into cloudy with promoting the circulation of blood, and interior feasible internal organs reach epidermis outward, so add Agkistrodon in prescription.But Caulis Lonicerae heat-clearing and toxic substances removing and dredge the meridian passage, Caulis Trachelospermi GUIXIN, liver two warps can be invigorated blood circulation in liver heat removing, dispelling wind and removing obstruction in the collateral, easing joint movement makes muscles and bones happy; Radix Clematidis dispels the wind, and wins temperature, and the logical the five internal organs of a surname are searched by all wind, make QI and blood must with, so write out a prescription the function of dredge the meridian passage is arranged.(3) relieve dizziness, high fever, infantile convulsions, epilepsy, etc. and decide the convulsion medicine, Chinese medicine think " wind excessive in interior, control with hot temperature ", Scolopendra can suppressing liver-wind to relieve spasm, its salty in the mouth and suffering with the heresy of diffusing wind, reach the irritability bar and the muscle normal pulse is smooth, liver-wind is relieving spasm to stop pain from putting out.Pheretima is the heresy of Li Wenre clearly, so the source of the living wind that can break.The Bombyx Batryticatus suppressing the hyperactive liver to relieve the wind syndrome, apoplexy person is a liver-wind stirring up internally, liver governing tendons is so have numb limbs and tense tendons, hemiplegia.Suppressing the hyperactive liver to relieve the wind syndrome can be removed the root of apoplexy.
Modern medicine proves with hemorheology and hemodynamics: the rheological characteristic of (1) blood and the change of blood viscosity are the major reasons that causes blood flow, flow velocity and change of flow state in blood circulation and the microcirculation, promptly form the major reason of apoplexy.The present invention contains a large amount of blood circulation promoting and blood stasis dispelling compositions, danshensu (Radix Salviae Miltiorrhizae), ligustrazine (Rhizoma Chuanxiong), Flos Carthami (Flos Carthami), Pheretima B1(Pheretima).(2) can accelerate erythrocyte electrophoresis speed, improve platelet, whole blood contrast viscosity, plasma viscosity and three indexs of fibrin of ischemia apoplexy patient are obviously descended because of ATP induces the electrophoresis that is produced slow.(3) ligustrazine can significantly strengthen the dissolution rate of thrombosis, and by Radix Salviae Miltiorrhizae, the Chinese medicine compound of compositions such as Semen Persicae also has dissolution to thrombosis.(4) Flos Carthami truly has remarkable protective effect to acute ischemia anoxia disease of brain.(5) drug for invigorating blood circulation and eliminating stasis such as Semen Persicae has the effect of blood vessel dilating, increasing blood flow, and the opening of capillary bed is increased, and blood flow is accelerated, and blood flow increases, thus the microcirculation improvement obstacle.(6) (Scorpio) such as Scorpio element, scorpion acid, trimethylamines, soap (Agkistrodon), Pheretima B1(Pheretima), aminoacid, vitamin A, B1, D, ergosterol etc. (Bombyx Batryticatus), they or act on the central nervous system, or vasoactive motorium or directly act on blood vessel, make vasodilation, be beneficial to brain and limbs blood supply.(7) Caulis Spatholobi has the obvious suppression thrombin to facilitate the fibrin source to become the existence of fibrin material under experiment condition, promptly in the presence of this medicine, even blood contacts with thrombin, can not form clot.
Prescription of the present invention not only has the function of blood circulation promoting and blood stasis dispelling, and can regulate the equilibrium between yin and yang of body internal organs, meridian qi and blood.Unobstructed vessel, negative and positive are flat secret, so type of deficiency of YIN leading to hyper activity of YANG is had curative effect preferably.Toxic and side effects of the present invention is little in addition, by liver, kidney and the repeated examinations of hemopoietic system many cases to clinical patients, does not find infringement.
The present invention is used for clinical showing and examines, by the traditional Chinese medical science four diagnostic methods, to apoplexy and sequela typing be: Qi deficiency blood stasis type (hemiplegia hemianesthesia; mouthful eye is oblique, and speech is not smoothgoing puckery, pale complexion, shortness of breath and fatigue, the mouth sialorrhea, from sweating, cardiopalmus just Tang, brothers' swelling, dimly pale tongue, thin white fur of tongue or white greasy, deep-thready pulse, carefully slow or thin string).Liver-kidney yin deficiency (hemiplegia, hemianesthesia, Kou Yan are tiltedly, tongue falls that speech is not smoothgoing, the dry stool constipation, have a dizzy spell, cough up phlegm or abundant expectoration, dimly red tongue, yellow fur or yellow greasy, stringy and rolling pulse or hemiplegia side stringy and rolling pulse and big).Type of deficiency of YIN leading to hyper activity of YANG (hemiplegia, hemianesthesia, Kou Yan tiltedly, tongue fall not smoothgoing, the irritated insomnia of speech, vertigo and tinnitus, feverish sensation in the palms and soles, deep red tongue or dark red, few tongue or no fur, thready and stringy pulse or thin stringy and rapid pulse) and other type (stroke patient does not belong to above four type persons).
The present invention in line with the principle of theory of Chinese medical science formulation evaluation criteria, with reference to modern medicine chamber inspection situation, is divided into recovery from illness about the evaluation of criterion of therapeutical effect, and produce effects takes a turn for the better invalid four classes; (the symptom Signs disappears substantially, and by original hemiplegia, limb function completely loses, and after treatment, the movable recovery normally taken care of oneself, or reworked, or slightly subjective symptoms is arranged, and aphasia or aphasia recover substantially, can normally talk in recovery from illness.Produce effects (symptom and sign obviously improves, and the limb activity degree increases, as limb function completely loses before treating, and can walk with the help of a staff after the treatment, and aphasia is understood language through treatment, but unclear).Take a turn for the better (symptom and sign partly improves, and limb activity has certain improvement).Invalid (symptom and sign does not have improvement or the automatic abandoning cure person of patient after treating).
The present invention all may be selected to be case (cerebral hemorrhage patient acute stage is not in the example of selection) to all cerebral infarction and ischemic, hemorrhagic apoplexy sequela patient, takes random sampling method to be divided into observation group and matched group.Be limited to the traditional Chinese medical science and be divided into affection by exogenous wind and syndrome similar to wind disease on concept for apoplexy, clinical difficult grasp, thus also can be with reference to Western medicine diagnose, as cerebral thrombosis, cerebral embolism, apoplexy sequela, subarachnoid hemorrhage sequela and part facial paralysis.
The present invention treats in apoplexy and the sequela clinical observation, and getting Chinese patent medicine of the same type " NAODESHENG " treatment group is matched group.
Table 1 level Four curative effect comparison sheet
Conclusion: learn by statistics and handle:
Two groups of effective percentage relatively, R=4.04>2.33(gets d=0.1R2.1-d=2.33) significant difference arranged.Be that observation group is than matched group curative effect height.
2. two groups of cure rates compare, and also there is significant difference in R=5.12>2.33.Be that observation group is than matched group cure rate height.
Table 2 disease type and curative effect comparision
Conclusion: this medicine is better to the hyperactivity of YANG due to deficiency of YIN curative effect as can be seen from the table.
There is certain influence at the discovery age to the treatment of primary disease in the clinical observation, so we have added up age and curative effect situation by the Pyatyi grouping.See table 3 for details.
Table 3 age and curative effect comparision
Conclusion: this medicine descends to some extent to age group curative effect more than 70 years old as can be seen from the table, and this explanation increases various functional activities with the age and descends, thereby effect is poor slightly.
Table 3 age and curative effect comparision
Conclusion: this medicine descends to some extent to age group curative effect more than 70 years old as can be seen from the table, and this explanation increases various functional activities with the age and descends, thereby effect is poor slightly.
Find also in the clinical observation that the curative effect and the course of disease are in close relations, also as follows by Pyatyi method of dividision into groups statistics.See table 4 for details:
Table 4 course of disease and curative effect comparision
Conclusion: as can be seen from the table, this medicine to the course of disease 1 year with interior person, curative effect is better, and is inferior slightly to course of disease elder curative effect.
Table 5
The present invention can think that the identical medical material of the property of medicine exchanges replacement, can replace with the Herba Lycopi such as Radix Salviae Miltiorrhizae, in like manner according to the Chinese medicine viewpoint, Rhizoma Chuanxiong and Rhizoma Curcumae, Radix Angelicae Sinensis and Radix Curcumae, Radix Clematidis and Herba Taxilli, Bungarus Parvus and Agkistrodon, Flos Carthami and blue Herba Linderniae Crustaceae, all interchangeable replacement of Caulis Spatholobi and Oletum Trogopterori.
Every pastille of the present invention weighs 0.4 gram, obeys two to four at every turn, obeys every day three times.
By prescriptions of Chinese medicine of the present invention can be made into tablet, capsule, electuary, pill, etc. different dosage form.
Advantage of the present invention be apoplexy and on the sequela convalescent care such as wind-induced hemiplegia, based on blood circulation promoting and blood stasis dispelling, dredge the meridian passage is auxilliary, relieve dizziness, high fever, infantile convulsions, epilepsy, etc. and decide convulsion for the former rule of prescription that assistant makes, prescription is made a distinction between the important and the lesser one, compatibility is reasonable, determined curative effect acts on gentlely, and side effect is little, and it is convenient that tablet has preparation, and dosage is accurate, steady quality, be easy to carry and take, total effective rate reaches 98% on the clinical observation curative effect, and particularly obvious effective rate reaches 32.56%, and cure rate reaches 36.43%.
Embodiment one: (below be weight percentage)
Radix Salviae Miltiorrhizae 11.15%, Rhizoma Chuanxiong 3.34%, Radix Angelicae Sinensis 3.34%, Flos Carthami 1.11%, Caulis Spatholobi 11.15%, Caulis Trachelospermi 6.69%, Radix Clematidis 3.34%, Herba Lycopodii 6.69%, Caulis Lonicerae 11.15%, Radix Cyathulae 11.15%, Fructus Chaenomelis 5.57%, Pheretima 10.03%, Bombyx Batryticatus 3.34%, Eupolyphaga Seu Steleophaga 3.34%, Scorpio 1.11%, Scolopendra 0.56%, Semen Persicae 3.34%, Fructus Leonuri 3.30%, Bungarus Parvus 0.22%.
Manufacture method of the present invention is that the Radix Salviae Miltiorrhizae of Radix Angelicae Sinensis during (1) will write out a prescription, Rhizoma Chuanxiong, Bungarus Parvus and 1/2 amount is made fine powder altogether, cross sieve No. 6, the direct crushing quantity of crude drug in whole is 30.1% of the prescription full dose, surplus medicinal water extraction is through filtering merging filtrate, leave standstill, precipitate and concentrating under reduced pressure (vacuum 400mmHg post, 75 ℃ ± 5 ℃) PROCESS FOR TREATMENT, make the extractum of regulation proportion.Add above fine powder, mixing, 80 ℃ of dryings add absorbent, with other adjuvant granulations, tabletting, coating.
Embodiment two:
The Herba Lycopi 11.15%, Rhizoma Chuanxiong 3.34%, Radix Angelicae Sinensis 3.34%, Flos Carthami 1.11%, Caulis Spatholobi 11.15%, Caulis Trachelospermi 6.69%, Radix Clematidis 3.34%, Herba Lycopodii 6.69%, Caulis Lonicerae 11.15%, Radix Cyathulae 11.15%, Fructus Chaenomelis 5.57%, Pheretima 10.03%, Bombyx Batryticatus 3.34%, Eupolyphaga Seu Steleophaga 3.34%, Scorpio 1.11%, Scolopendra 0.56%, Semen Persicae 3.34%, Fructus Leonuri 3.30%, Bungarus Parvus 0.22%.
Manufacture method is with embodiment one, and just the Flos Carthami full dose participates in extracting.
Embodiment three:
Radix Salviae Miltiorrhizae 11.15%, Rhizoma Curcumae 3.34%, Radix Angelicae Sinensis 3.34%, Flos Carthami 1.11%, Caulis Spatholobi 11.15%, Caulis Trachelospermi 6.69%, Radix Clematidis 3.34%, Herba Lycopodii 6.69%, Caulis Lonicerae 11.15%, Radix Cyathulae 11.15%, Fructus Chaenomelis 5.57%, Pheretima 10.03%, Bombyx Batryticatus 3.34%, Eupolyphaga Seu Steleophaga 3.34%, Scorpio 1.11%, Scolopendra 0.56%, Semen Persicae 3.34%, Fructus Leonuri 3.30%, Bungarus Parvus 0.22%.
Manufacture method is with embodiment one.
Embodiment four:
Radix Salviae Miltiorrhizae 11.15%, Rhizoma Chuanxiong 3.34%, Radix Curcumae 3.34%, Flos Carthami 1.11%, Caulis Spatholobi 11.15%, Caulis Trachelospermi 6.69%, Radix Clematidis 3.34%, Herba Lycopodii 6.69%, Caulis Lonicerae 11.15%, Radix Cyathulae 11.15%, Fructus Chaenomelis 5.67%, Pheretima 10.03%, Bombyx Batryticatus 3.34%, Eupolyphaga Seu Steleophaga 3.34%, Scorpio 1.11%, Scolopendra 0.56%, Semen Persicae 3.34%, Fructus Leonuri 3.30%, Bungarus Parvus 0.22%.
Manufacture method is with embodiment one.
Embodiment five:
Radix Salviae Miltiorrhizae 11.15%, Rhizoma Chuanxiong 3.34%, Radix Angelicae Sinensis 3.34%, Flos Carthami 1.11%, Caulis Spatholobi 11.15%, Caulis Trachelospermi 6.69%, Herba Taxilli 3.34%, Herba Lycopodii 6.69%, Caulis Lonicerae 11.15%, Radix Cyathulae 11.15%, Fructus Chaenomelis 5.57%, Pheretima 10.03%, Bombyx Batryticatus 3.34%, Eupolyphaga Seu Steleophaga 3.34%, Scorpio 1.11%, Scolopendra 0.56%, Semen Persicae 3.34%, Fructus Leonuri 3.30%, Bungarus Parvus 0.22%.
Manufacture method is with embodiment one.
Embodiment six:
Radix Salviae Miltiorrhizae 11.15%, Rhizoma Curcumae 3.34%, Radix Angelicae Sinensis 3.34%, Flos Carthami 1.11%, Caulis Spatholobi 11.15%, Caulis Trachelospermi 6.69%, Radix Clematidis 3.34%, Herba Lycopodii 6.69%, Caulis Lonicerae 11.15%, Radix Cyathulae 11.15%, Fructus Chaenomelis 5.57%, Pheretima 10.03%, Bombyx Batryticatus 3.34%, Eupolyphaga Seu Steleophaga 3.34%, Scorpio 1.11%, Scolopendra 0.56%, Semen Persicae 3.34%, Fructus Leonuri 3.30%, Bungarus Parvus 0.22%.
Manufacture method is with embodiment one.
Embodiment seven:
Radix Salviae Miltiorrhizae 11.15%, Rhizoma Chuanxiong 3.34%, Radix Angelicae Sinensis 3.34%, Herba Leonuri 1.11%, Caulis Spatholobi 11.15%, Caulis Trachelospermi 6.69%, Radix Clematidis 3.34%, Herba Lycopodii 6.69%, Caulis Lonicerae 11.15%, Radix Cyathulae 11.15%, Fructus Chaenomelis 5.57%, Pheretima 10.03%, Bombyx Batryticatus 3.34%, Eupolyphaga Seu Steleophaga 3.34%, Scorpio 1.11%, Scolopendra 0.56%, Semen Persicae 3.34%, Fructus Leonuri 3.30%, Bungarus Parvus 0.22%.
Manufacture method is with embodiment one.
Embodiment eight:
Radix Salviae Miltiorrhizae 11.15%, Rhizoma Chuanxiong 3.34%, Radix Angelicae Sinensis 3.34%, Flos Carthami 1.11%, Oletum Trogopterori 11.15%, Caulis Trachelospermi 6.69%, Radix Clematidis 3.34%, Herba Lycopodii 6.69%, Caulis Lonicerae 11.15%, Radix Cyathulae 11.15%, Fructus Chaenomelis 5.57%, Pheretima 10.03%, Bombyx Batryticatus 3.34%, Eupolyphaga Seu Steleophaga 3.34%, Scorpio 1.11%, Scolopendra 0.56%, Semen Persicae 3.34%, Fructus Leonuri 3.30%, Bungarus Parvus 0.22%.
Manufacture method is with embodiment one.
Claims (2)
1, a kind of Chinese patent medicine tablet for the treatment of the apoplexy and the sequela of commonly encountered diseases of internal department, frequently-occurring disease includes outer sugar-coat and forms, and it is characterized in that writing out a prescription and the percentage by weight of each composition is:
Radix Salviae Miltiorrhizae 7-15%, Rhizoma Chuanxiong 2-4%, Radix Angelicae Sinensis 2-4%, Flos Carthami 0.7-1.5%, Caulis Spatholobi 7-15%, Caulis Trachelospermi 4-8%, Radix Clematidis 2.5-4.5%, Herba Lycopodii 4.5-8.5%, Caulis Lonicerae 7-15%, river wood knee joint 7-15%, Fructus Chaenomelis 3-7%, Pheretima 8.5-13.8%, Bombyx Batryticatus 2.3-4.3%, Eupolyphaga Seu Steleophaga 2.3-4.3%, Scorpio 0.6-1.5%, Scolopendra 0.3-0.7%, Semen Persicae 2.3-4.5%, Fructus Leonuri 2.5-4.0%, Bungarus Parvus 0.10-0.30%.
2, the apoplexy of treatment commonly encountered diseases of internal department according to claim 1, frequently-occurring disease and the Chinese patent medicine tablet of sequela is characterized in that best prescription is:
Radix Salviae Miltiorrhizae 11.15%, Rhizoma Chuanxiong 3.34%, Radix Angelicae Sinensis 3.34%, Flos Carthami 1.11%, Caulis Spatholobi 11.15%, Caulis Trachelospermi 6.69%, Radix Clematidis 3.34%, Herba Lycopodii 6.69%, Caulis Lonicerae 11.15%, Radix Cyathulae 11.15%, Fructus Chaenomelis 5.57%, Pheretima 10.03%, Bombyx Batryticatus 3.34%, Eupolyphaga Seu Steleophaga 3.34%, Scorpio 1.11%, Scolopendra 0.56%, Semen Persicae 3.34%, Fructus Leonuri 3.30%, Bungarus Parvus 0.22%.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 93100576 CN1081888A (en) | 1993-01-01 | 1993-01-01 | Treatment commonly encountered diseases of internal department, the apoplexy of frequently-occurring disease and the Chinese patent medicine tablet of sequela |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 93100576 CN1081888A (en) | 1993-01-01 | 1993-01-01 | Treatment commonly encountered diseases of internal department, the apoplexy of frequently-occurring disease and the Chinese patent medicine tablet of sequela |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1081888A true CN1081888A (en) | 1994-02-16 |
Family
ID=4983104
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 93100576 Pending CN1081888A (en) | 1993-01-01 | 1993-01-01 | Treatment commonly encountered diseases of internal department, the apoplexy of frequently-occurring disease and the Chinese patent medicine tablet of sequela |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1081888A (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1054046C (en) * | 1994-12-31 | 2000-07-05 | 铁道部第二工程局职业病防治院 | Lycopodium clavatum injection and its preparation method |
CN1076202C (en) * | 1999-04-20 | 2001-12-19 | 赵荣春 | Prescription of Tongluofutanwan as medicine for activating collaterals and rehabilitating paralysis and preparing method thereof |
CN1100551C (en) * | 2000-08-23 | 2003-02-05 | 唐玉璋 | Instant particles 'Xinnaotong' for treating heart and brain diseases |
CN101884737A (en) * | 2010-07-14 | 2010-11-17 | 毛顺卿 | Chinese medicinal composition for treating hemiparalysis |
CN101244239B (en) * | 2008-03-07 | 2010-12-08 | 向祚伟 | Chinese medicine for treating apoplexy hemiplegia sequela |
CN105362740A (en) * | 2015-11-16 | 2016-03-02 | 宁国仙霞骨伤医院 | Traditional Chinese medicine composition for treatment of stroke and application thereof |
CN109248227A (en) * | 2017-07-14 | 2019-01-22 | 徐定清 | A kind of active medicine pill for chasing after wind pellet of apoplexy |
-
1993
- 1993-01-01 CN CN 93100576 patent/CN1081888A/en active Pending
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1054046C (en) * | 1994-12-31 | 2000-07-05 | 铁道部第二工程局职业病防治院 | Lycopodium clavatum injection and its preparation method |
CN1076202C (en) * | 1999-04-20 | 2001-12-19 | 赵荣春 | Prescription of Tongluofutanwan as medicine for activating collaterals and rehabilitating paralysis and preparing method thereof |
CN1100551C (en) * | 2000-08-23 | 2003-02-05 | 唐玉璋 | Instant particles 'Xinnaotong' for treating heart and brain diseases |
CN101244239B (en) * | 2008-03-07 | 2010-12-08 | 向祚伟 | Chinese medicine for treating apoplexy hemiplegia sequela |
CN101884737A (en) * | 2010-07-14 | 2010-11-17 | 毛顺卿 | Chinese medicinal composition for treating hemiparalysis |
CN105362740A (en) * | 2015-11-16 | 2016-03-02 | 宁国仙霞骨伤医院 | Traditional Chinese medicine composition for treatment of stroke and application thereof |
CN109248227A (en) * | 2017-07-14 | 2019-01-22 | 徐定清 | A kind of active medicine pill for chasing after wind pellet of apoplexy |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1095610A (en) | The pharmaceutical preparation Fubingkang of treatment, prevention gynecological diseases | |
CN102139030A (en) | Oral Chinese herbal preparation for treating gingivitis and preparation method thereof | |
CN1051237C (en) | Meicinal prepn. "Kexianling" for curing epilepsy | |
CN1539447A (en) | Medicated rehabilitation wine for treating premonitory apoplexy, sequela of apoplexy and obastrcution of qi in chest | |
CN1390585A (en) | Chinese medicine for detoxication purpose and its preparing process | |
CN100586458C (en) | Medicine for treating cerebral apoplexy | |
CN1288748A (en) | Medicine for treating cardiac and cerebral vascular diseases and its preparation | |
CN1232266C (en) | Chinese medicinal capsules for apoplexy and thoracic palsy and preparation thereof | |
CN1081888A (en) | Treatment commonly encountered diseases of internal department, the apoplexy of frequently-occurring disease and the Chinese patent medicine tablet of sequela | |
CN1112424A (en) | Toutongning-medicine for headache | |
CN1541676A (en) | Health care medicine for enriching blood in puerperium and its preparation and uses | |
CN1049351C (en) | Chinese patent medicine for curing cerebrovascular disease | |
CN1840004A (en) | Blood-activating stasis-resolving mixture and preparation method thereof | |
CN1254254C (en) | Chinese patent drug for treating nasosinusitis | |
CN1440804A (en) | Antilipemic Chinese medicine | |
CN107080786A (en) | Antidepressant compositions and its preparation method and application and medicine or pharmaceutical composition comprising it | |
CN102274334A (en) | Medicine for treating rhinitis and preparation method thereof | |
CN1520862A (en) | Prepared traditional Chinese medicine for apoplexy and obstruction of qi in the chest | |
CN1086586C (en) | Medicine for treating cardiac and cerebral vascular diseases and its preparation | |
CN116966247B (en) | Traditional Chinese medicine composition and medicine for treating cerebral edema | |
CN118477132B (en) | Traditional Chinese medicine composition for treating allergic rhinitis | |
CN1308952A (en) | Chinese medicine for treating trigeminal neuraligia and its preparing process | |
CN1076622C (en) | Chinese medicine for curing nephritis | |
CN108578549B (en) | Medicine for treating acne and application thereof | |
CN117919363A (en) | Traditional Chinese medicine composition for treating sleep disorder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C01 | Deemed withdrawal of patent application (patent law 1993) | ||
WD01 | Invention patent application deemed withdrawn after publication |